After eight years with the company, Clark will vacate his post on Monday (16 April) to become chief executive at Destiny Pharma.
He will remain on the board of PrimeVigilance as a non-executive director and consultant.
Jan Petracek will replace Clark and step into the role of chief executive of the subsidiary straight away.
Petracek joined the company last November as chief executive of European PharmInvent Services following its acquisition and subsequent integration into PrimeVigilance.
“We are fortunate to have in the wings a replacement CEO of the calibre of Jan Petracek,” said Ergomed chief executive Miroslav Reljanovic.
“As founder of PharmInvent and former regulator at EMA, his unique combination of entrepreneurship and specialist pharmacovigilance expertise will serve to drive forward our pharmacoviglance businesses.”